We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
A yearlong internal power struggle for control of Chinese vaccine maker Sinovac Biotech has spilled from the boardroom to the production floor, forcing the company to suspend manufacturing of its hepatitis A vaccine.